News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer
Breast Cancer
Jan 12, 2025, 08:51

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:

“Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.”

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial | Journal of Clinical Oncology

Authors: Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada,  Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kei Koizumi,  Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda.

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Akiyo Yoshimura cancer Elisabetta Bonzano Hiroki Hasegawa Hiroshi Tada Junji Tsurutani Kazuhiro Araki Kei Koizumi Masahiro Kitada Masato Takahashi Michiko Tsuneizumi Natsuko Mori Norikazu Masuda OncoDaily Oncology Satoshi Morita Shigehira Saji Toru Higuchi Toshimi Takano Toshinari Yamashita Tsuguo Iwatani Tsutomu Iwasa Yohei Uchida Yoichi Naito
Special Coverage
Blog
May 1, 2025, 20:49
Jennifer Bires: Patients Carrying Private Fears They Were Too Overwhelmed to Share
Blog
May 1, 2025, 20:14
NCI Center for Global Health Highlights Challenges of Conducting Cancer Trials in LMICs
Blog
May 1, 2025, 19:53
CCI4EU: A European Initiative Supporting Cancer Research and Innovation - ESO
Blog
May 1, 2025, 19:21
Rima Torosyan: Grateful to be part of the Retinoblastoma Workshop at the POEM Group’s 4th Scientific Meeting
Blog
May 1, 2025, 19:08
Jasmine Kamboj: Fantastic conversations on AI in Oncology with trailblazers
Blog
May 1, 2025, 18:56
Hadieh Eslampanah is Participating in the 17th CCI and SIOP Asia Riyadh 2025 Conference as a Board Member
Blog
May 1, 2025, 18:24
Alique Topalian: Advancing Cancer Interception Through AACR’s Scientist-to-Survivor Program
Blog
May 1, 2025, 18:12
Alastair Lamb highlights BJUI session on AI and Medicolegal topics at AUA25
Blog
May 1, 2025, 18:05
Misty Dawn Shields: An amazing night at the "Evening of Promise" gala hosted by American Lung Association
Blog
May 1, 2025, 18:04
Karuna Ganesh reveals E. coli’s role in early-onset colorectal cancer Initiation at AACR25
Drugs
May 1, 2025, 17:54
Zongertinib breakthrough: Elizabeth McKenna highlights new study on HER2-driven cancers
Insight
May 1, 2025, 17:49
Miguel Bronchud shared insights on the tumor microenvironment in cancer progression